BioNTech SE (BNTX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Advancements ...
BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.
BioNTech (BNTX) Scheduled to Post Quarterly Earnings on Monday
BioNTech (NASDAQ:BNTX – Get Free Report) will be announcing its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter.
BioNTech to Report Q3 Earnings: Is a Beat in the Cards?
We expect BioNTech SE BNTX to surpass expectations when it reports third-quarter 2024 results on Nov. 4, before the opening bell. Let’s see how things have shaped up for the quarter to be reported. Factors at Play BioNTech’s top line currently includes sales from its mRNA-based COVID-19 vaccine,
Marqeta (MQ) Q3 2024 Earnings Call Transcript
At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator instructions] As a reminder, this conference is being recorded.
Brightcove Inc. (BCOV) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ETCompany ParticipantsMarc DeBevoise - Chief Executive
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Nov 04, 2024, 5:00 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Partici
BioNTech Se (BNTX) Q3 2024 Earnings Call Transcript
Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz director, investor relations. Please go ahead. Michael Horowicz-- Vice President,
Forward Air Corporation (FWRD) Q3 2024 Earnings Call Transcript
Welcome to the Forward Air's Third Quarter 2024 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode and the floor will be open for your questions following the presentation.
Jefferies Reaffirms Their Buy Rating on BioNTech SE (BNTX)
Jefferies analyst Akash Tewari maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $150.00.
BioNTech SE Reports Strong Revenue Growth Amid Rising R&D Costs
BioNTech SE (BNTX) has released an update. BioNTech SE’s quarterly report for the period ending September 30, 2024, reveals a ...
Why is Pfizer stock falling after Q3 results?
Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...
Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...
2,051 Shares in BioNTech SE (NASDAQ:BNTX) Purchased by Mount Yale Investment Advisors LLC
Mount Yale Investment Advisors LLC acquired a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) in the third quarter, according to the company in its most recent 13F filing with the ...
Pfizer raises guidance as COVID franchise drives Q3 beat
Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance ...
Morningstar5d
BioNTech SE ADR BNTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Yahoo Finance11d
BioNTech SE (BNTX)
MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, ...
Cautious Outlook on BioNTech SE: Strong Q3 Performance Overshadowed by Uncertain Future in Vaccine Sales and Oncology Pipeline
BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yaron Werber ...